TMCnet News
Genomics England and Cambridge Cancer Genomics (CCG.ai) announce immunotherapy partnershipCAMBRIDGE, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- Genomics England, the Department of Health and Social Care’s genomics spin-out, and Cambridge Cancer Genomics (CCG.ai), a precision AI platform company, announced today a broad partnership to improve UK-patient access to immune-system modulating cancer drugs (immunotherapies), monitor treatment effectiveness over time, and rapidly identify resistance to these drugs. Immunotherapies are fast becoming one of our most effective tools to fight cancer, working by stimulating a patient’s immune system to attack cancer. By leveraging the immune system’s own precise, adaptive defences against tumours, immunotherapy has the potential to be a universal answer to cancer. Building on the data from Genomics England’s 100,000 genomes project and CCG.ai’s expertise in AI-driven cancer diagnostics, a long term partnership between the two companies is announced today. This includes CCG.ai’s membership of Genomics England’s industry network (Discovery Forum), and a collaborative research project that has yielded a ‘sequencing-panel’ designed to cost-effectively profile overall tumour mutational burden (TMB), a measure that can help indicate response to immunotherapies. The new panel also incorporates genes known to correlate with treatment response and treatment resistance to immuno-oncology drugs. It is hoped that this sequencing panel will reduce the cost of assessing the effectiveness of immunotherapies. When twinned with CCG.ai’s ‘liquid biopsy’ technology - using AI to accurately analyse cancer tumour DNA in a blood sample - this panel could also allow TMB to be calculated from a patient's blood, and serial samples could tell an oncologist when a tumour is becoming resistant to immunotherapy. Stratification of responders and non-responders will also reduce the effective cost of immunotherapies and may increase access to this new drug class in the NHS.
Full Release: About Us: Press Enquiries: |